These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34537761)

  • 1. Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice.
    Khin PP; Hong Y; Yeon M; Lee DH; Lee JH; Jun HS
    Aging (Albany NY); 2021 Sep; 13(18):21962-21974. PubMed ID: 34537761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.
    Hong Y; Lee JH; Jeong KW; Choi CS; Jun HS
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):903-918. PubMed ID: 31020810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle immobilization and remobilization downregulates PGC-1α signaling and the mitochondrial biogenesis pathway.
    Kang C; Ji LL
    J Appl Physiol (1985); 2013 Dec; 115(11):1618-25. PubMed ID: 23970536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
    Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
    Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
    Yu M; Van Brunt K; Varnado OJ; Boye KS
    Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
    Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
    Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
    de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
    Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
    Reaney M; Yu M; Lakshmanan M; Pechtner V; van Brunt K
    Diabetes Obes Metab; 2015 Sep; 17(9):896-903. PubMed ID: 26095190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
    Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure.
    Tang K; Wagner PD; Breen EC
    J Cell Physiol; 2010 Feb; 222(2):320-7. PubMed ID: 19859910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
    de la Peña A; Cui X; Geiser J; Loghin C
    Clin Pharmacokinet; 2017 Nov; 56(11):1415-1427. PubMed ID: 28357715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
    Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
    Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel hindlimb immobilization procedure for studying skeletal muscle atrophy and recovery in mouse.
    Caron AZ; Drouin G; Desrosiers J; Trensz F; Grenier G
    J Appl Physiol (1985); 2009 Jun; 106(6):2049-59. PubMed ID: 19342435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.